Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
BACKGROUND
The acid suppressive effects of omeprazole (OPZ) and lansoprazole (LPZ) are influenced by the CYP2C19 polymorphism. On the other hand, some investigators have reported that acid suppressive effect of rabeprazole (RPZ) was not significantly affected by CYP2C19. The present study was designed to investigate whether the CYP2C19 genotype is related to the healing of reflux esophagitis (RE) in treatment with RPZ 10 mg.


METHODS
One hundred and three Japanese patients with RE were treated with daily oral administration of 10 mg RPZ. At 4 and 8 weeks after the start of treatment, healing of RE was evaluated endoscopically. The CYP2C19 genotype was investigated before the treatment.


RESULTS
At 4 weeks after the start of treatment, the healing rates for homo-extensive metabolizer, hetero-extensive metabolizer, and poor metabolizer patients were 83.3% (15/18), 77.3% (17/22), and 88.9% (8/9) [corrected] respectively, and at 8 weeks after the start of treatment, the healing rates were 86.1% (31/36), 92.0% (46/50), and 82.4% (14/17), respectively. There were no significant differences in the healing rate of RE among the three genotypes at either 4 or 8 weeks after the start of treatment.


CONCLUSIONS
The therapeutic effects of 10 mg/day RPZ administration on RE may be uninfluenced by the CYP2C19 polymorphism.
Ariizumi
Ken
K
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. kariizumi@int3.med.tohoku.ac.jp
Ohara
Shuichi
S
Koike
Tomoyuki
T
Inomata
Yoshifumi
Y
Iijima
Katsunori
K
Sekine
Hitoshi
H
Noguchi
Mitsunori
M
Sugiyama
Koichi
K
Eda
Yoshiki
Y
Kayaba
Shoichi
S
Kawamura
Msashi
M
Shimosegawa
Tooru
T
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005755:Gastrins / Q000097:blood; D016481:Helicobacter Infections / Q000175:diagnosis; D006551:Hernia, Hiatal; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010435:Pepsinogens / Q000097:blood; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D064750:Rabeprazole; D014945:Wound Healing
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D005755:Gastrins; D010435:Pepsinogens; D064750:Rabeprazole; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19